Relmada Therapeutics (RLMD)

• Market cap: $801M
• 1 day: 1.6%
• 5 days: 5.96%
• 1 month: 7.61%
• 3 months: 99.48%
• 6 months: 247.27%
• Year to date: 74.83%
• 1 year: 2,084.73%
• 5 years: -80.01%
• 10 years: -30.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Employees: 17